DR. JENNIFER A VELTMAN M.D.
Prescription History 1356599310
Internal Medicine - Infectious Disease in Loma Linda, CA


Quality Rating: 85.18 out of 100 score

NPI Status: Active since September 03, 2008

Contact Information

11234 ANDERSON ST # MC-1516
LOMA LINDA, CA
ZIP 92354
Phone: (909) 558-4499

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. JENNIFER A VELTMAN M.D., an active Infectious Disease specialist practicing in Loma Linda, CA. Our medical registry currently tracks 8 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 170 documented patient claims. Among these therapy options, the most frequently utilized medication is Biktarvy, which accounts for 44 claims alone.

Medication Index


Biktarvy

Generic Formulation: Bictegrav/Emtricit/Tenofov AlaSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 44
30-Day Fills 58.0
Days Supply 1,740
CA State Average Benchmarks
Peer Average Claims74.0
Peer Average 30-Day Fills86.5
Peer Average Days Supply2,570
Conservative Utilization

This provider writes prescriptions for this formulation 40.5% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $233,951.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$5,317.08

State Avg Cost Per Claim

$4,266.43

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This combination product is used by itself to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of 3 different drugs: bictegravir, emtricitabine, and tenofovir alafenamide. Bictegravir is called an integrase strand transfer inhibitor-INSTI. Emtricitabine is called a nucleoside reverse transcriptase inhibitor, while tenofovir alafenamide is called a nucleotide reverse transcriptase inhibitor. Emtricitabine and tenofovir alafenamide are often called NRTIs. Bictegravir/emtricitabine/tenofovir alafenamide is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Cabenuva

Generic Formulation: Cabotegravir/RilpivirineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
CA State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills33.2
Peer Average Days Supply984
Conservative Utilization

This provider writes prescriptions for this formulation 45.8% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $62,261.76 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,789.37

State Avg Cost Per Claim

$5,885.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to help control HIV infection. It contains 2 medications: cabotegravir and rilpivirine. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Cabotegravir is an integrase inhibitor while rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI). Both drugs block the virus from growing and infecting more cells. Cabotegravir/rilpivirine is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Dovato

Generic Formulation: Dolutegravir Sodium/LamivudineSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 36
30-Day Fills 38.0
Days Supply 1,140
CA State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills40.9
Peer Average Days Supply1,226
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $110,866.92 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,079.64

State Avg Cost Per Claim

$3,000.68

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 2 drugs: dolutegravir and lamivudine. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Lamivudine belongs to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Dolutegravir belongs to a class of drugs known as integrase inhibitors. This medication is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Doxycycline Hyclate

Generic Formulation: Doxycycline HyclateSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 15.0
Days Supply 448
CA State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills30.9
Peer Average Days Supply512
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 59.3% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $360.26 across this reporting matrix range.

Provider Avg Cost Per Claim

$32.75

State Avg Cost Per Claim

$30.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic tetracycline derivative with similar antimicrobial activity.

Therapeutic Applications

This medication is used to treat a wide variety of bacterial infections, including those that cause acne. This medication is also used to prevent malaria. This medication is known as a tetracycline antibiotic. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Itraconazole

Generic Formulation: ItraconazoleSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
CA State Average Benchmarks
Peer Average Claims22.0
Peer Average 30-Day Fills28.2
Peer Average Days Supply795
Conservative Utilization

This provider writes prescriptions for this formulation 45.5% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,730.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$227.56

State Avg Cost Per Claim

$346.82

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole antifungal agent that inhibits cytochrome P-450-dependent enzymes required for ERGOSTEROL synthesis.

Therapeutic Applications

Itraconazole is used to treat a variety of fungal infections. It belongs to a class of drugs known as azole antifungals. It works by stopping the growth of fungi.

Prezcobix

Generic Formulation: Darunavir/CobicistatSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 21
30-Day Fills 25.0
Days Supply 750
CA State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills43.0
Peer Average Days Supply1,280
Conservative Utilization

This provider writes prescriptions for this formulation 40.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $60,014.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,857.82

State Avg Cost Per Claim

$2,823.95

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used with other HIV medications to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. This product is a combination of two different drugs: darunavir and cobicistat. Darunavir belongs to a class of drugs known as protease inhibitors. Cobicistat is used to increase (boost) the levels of darunavir. Darunavir/cobicistat is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Sulfamethoxazole-Trimethoprim

Generic Formulation: Sulfamethoxazole/TrimethoprimSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 14
30-Day Fills 18.0
Days Supply 525
CA State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills27.8
Peer Average Days Supply371
Conservative Utilization

This provider writes prescriptions for this formulation 44.0% less frequently than the standard regional baseline metric for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $292.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.87

State Avg Cost Per Claim

$5.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination with broad-spectrum antibacterial activity against both gram-positive and gram-negative organisms. It is effective in the treatment of many infections, including PNEUMOCYSTIS PNEUMONIA in AIDS.

Therapeutic Applications

This medication is a combination of two antibiotics: sulfamethoxazole and trimethoprim. It is used to treat a wide variety of bacterial infections (such as middle ear, urine, respiratory, and intestinal infections). It is also used to prevent and treat a certain type of pneumonia (pneumocystis-type). This medication should not be used by children less than 2 months of age due to the risk of serious side effects. This medication treats only certain types of infections. It will not work for viral infections (such as flu). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Triumeq

Generic Formulation: Abacavir/Dolutegravir/LamivudiSpecialty: Infectious Disease
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 570
CA State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills48.1
Peer Average Days Supply1,420
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.7% less volume than the regional standard for practitioners inside CA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $68,095.68 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,583.98

State Avg Cost Per Claim

$3,958.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product contains 3 drugs: abacavir, dolutegravir, and lamivudine. It is used to help control HIV infection. It helps to decrease the amount of HIV in your body so your immune system can work better. This lowers your chance of getting HIV complications (such as new infections, cancer) and improves your quality of life. Abacavir and lamivudine belong to a class of drugs known as nucleoside reverse transcriptase inhibitors (NRTIs). Dolutegravir belongs to a class of drugs known as integrase inhibitors. This medication is not a cure for HIV infection. To decrease your risk of spreading HIV disease to others, continue to take all HIV medications exactly as prescribed by your doctor. Use an effective barrier method (latex or polyurethane condoms/dental dams) during sexual activity as directed by your doctor. Do not share personal items (such as needles/syringes, toothbrushes, and razors) that may have contacted blood or other body fluids. Consult your doctor or pharmacist for more details.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. JENNIFER A VELTMAN M.D. provides transparency into local medical care patterns within Loma Linda, CA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Infectious Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.